Menstrual induction with the PGF2alpha-analogue ICI 81008.
"Menstrual Induction" (MI) has been studied in 79 volunteers, using the therapeutic principle of "PG-Impact". The PGF2alpha analogue: ICI 81008 was administered under strictly aseptic precautions into the uterine cavity during the 4th week of pregnancy. The treatment catheter (inserted through the cervical canal) delivered a single dose of only 100-200 mug ICI 81008 during the pilot study with this new drug. When it was established that the side effects were acceptable, this moderately effective dose was increased at first to 200-300 mug and eventually to 400 mug. At the 400 mug dose level, 29 (76%) of the 38 study patients had complete and 8 (21%) incomplete abortions, while 1 (3%) failed to bleed. Those 9 women who had incomplete abortions or failed to abort were curetted. In comparison with PGF2alpha (428 cases) and PGE2 (114 cases), ICI 81008 (38 cases at the 400 mug level) provoked lesser side effects, excepting the transient increase in blood pressure. All patients (whose intrauterine pressure was measured) responded to the ICI 81008-impact with rapidly developing high level uterine contracture. Plasma progesterone decreased significantly if treatment was successful and insignificantly in cases of treatment failure. In current studies, the efficacy of the vaginal delivery system of ICI 81008 is examined.
D000028:Abortion, Induced; D000328:Adult; D003967:Diarrhea / Q000139:chemically induced; D005260:Female; D006801:Humans; D007267:Injections; D008598:Menstruation; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011312:Pressure; D011374:Progesterone / Q000097:blood; D011458:Prostaglandins E / Q000627:therapeutic use; D011460:Prostaglandins F / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014599:Uterus; D014839:Vomiting / Q000139:chemically induced
D011458:Prostaglandins E; D011460:Prostaglandins F; D011374:Progesterone